Compare GSBC & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | TXMD |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.3M | 24.4M |
| IPO Year | 1996 | 2012 |
| Metric | GSBC | TXMD |
|---|---|---|
| Price | $73.32 | $2.27 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | ★ 77.8K | 54.5K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | 17.68 | ★ 73.68 |
| EPS | ★ 1.58 | 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.56 | N/A |
| P/E Ratio | ★ $47.32 | $229.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $53.76 | $0.98 |
| 52 Week High | $76.92 | $2.95 |
| Indicator | GSBC | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 66.37 |
| Support Level | $60.23 | $2.10 |
| Resistance Level | N/A | $2.32 |
| Average True Range (ATR) | 2.09 | 0.14 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 45.99 | 80.65 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.